Navigating Three BCMA-Targeted Modalities and Their Optimal Sequencing in Myeloma
This narrative review synthesizes efficacy, toxicity, and sequencing data across CAR-T, bispecific antibody, and antibody-drug conjugate platforms directed at B-cell maturation antigen (BCMA), giving pharmacists a framework for regimen selection in relapsed/refractory multiple myeloma.
📅 Journal publication: Jul 2026(online Dec 15, 2025)·Last updated: Oct 5, 2026
BCMA-targeted therapies revolutionize multiple myeloma care, balancing efficacy with unique toxicities.
BCMA-targeted therapies have transformed multiple myeloma treatment due to their specific targeting and improved patient outcomes. Cil-cel shows promising long-term remission, while BsAb therapies offer flexible options but risk T-cell exhaustion and ADCs face ocular toxicity challenges. Understanding therapy characteristics and sequencing is crucial to optimize patient outcomes and manage unique adverse effects effectively. BCMA-targeted therapies require strategic sequencing to maximize efficacy and manage distinct side effects.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Mihara K, Miyama T
Citation:Mihara K, Miyama T Characteristics and utilization of the three BCMA-targeted therapies in multiple myeloma. International journal of hematology. 2026;124(1):31-37. doi:10.1007/s12185-025-04128-4